Zynex, Inc.

ZYXIQ • Medical - Distribution

$0.13

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 sept 2025

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$3.79M

Crecimiento

-4.6%

Flujo de caja

4/5

Tendencia

Mostly stable

Evidencia

Crecimiento positivo de ingresos · 29.4%Flujo de caja libre positivo · 0.38Flujo de caja libre consistente · 4/5Liquidez saludable · 4.46Múltiplo de ganancias caro · 85.45

Datos financieros hasta: 30 sept 2025, 12:00 a.m. UTCÚltima actualización de earnings: 17 nov 2025, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:27 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.13

Change0.00%

Shares Out30.31M

Market Cap$3.79M

Enterprise Value$54.30M

52W Range0.02 - 0.77

Beta1.08

P/E-0.05

P/S0.04

P/B-0.09

P/FCF-0.18

EV/Sales0.50

Price$0.13

Change0.00%

Shares Out30.31M

Market Cap$3.79M

Enterprise Value$54.30M

52W Range0.02 - 0.77

Beta1.08

P/E-0.05

P/S0.04

P/B-0.09

P/FCF-0.18

EV/Sales0.50

EV/EBITDA-0.84

EV/FCF-2.59

FCF Yield-554.12%

Dividend Yield0.00%

Gross Margin79.50%

Oper. Margin3.11%

Profit Margin1.56%

Debt/Eq2.07

Current Ratio4.46

Quick Ratio3.63

Revenue 5Y-4.58%

FCF 5Y-10.93%

Target$14.38

Target Upside11404.00%

Target Median$14.25

Target Range11.00 - 18.00

Volume63.29K

Avg Volume100.97K

EPS Surprise-0.22

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

27/100

Fortaleza financiera

Deuda, caja, estabilidad

59/100

Potencial de crecimiento

Ingresos y expansión

95/100

Atractivo del precio

Barata o cara hoy

50/100

Por qué este puntaje▼

Crecimiento positivo de ingresos · 29.4%Flujo de caja libre positivo · 0.38Flujo de caja libre consistente · 4/5Liquidez saludable · 4.46Múltiplo de ganancias caro · 85.45Nivel de deuda alto · 2.07

Analyst view

Analyst sentiment and price target

ZYXI

Analyst sentiment

Based on 9 analyst votes · 2026-09-05

83/100

Bullish

Hold

Bearish

Precio objetivo

2026-06-06

Bajo

$11.00

Promedio

$14.38

Mediana

$14.25

Alto

$18.00

Resumen de la compañía

IPO: 2/25/2004

Industria: Medical - Distribution

P/B i: -0.09

Deuda / Patrimonio i: 2.07

Margen operativo: 3.11%

Margen neto: 1.56%

ROE i: -

ROIC: -

Salud financiera

Puntaje12 / 20

Deuda / Patrimonio: 2.07

Ratio corriente: 4.46

Ratio rápido: 3.63

Estado: Good

Advertencias

High debt level

Transacciones internas

Actividad reciente de ejecutivos e insiders

Cress Michael D

Transacción: 03/26/2026

VENTA

Cambio

-82,501

Precio

Not reported

Presentación

03/27/2026

Tipo

VENTA

Cress Michael D

Transacción: 03/26/2026

VENTA

Cambio

-12,499

Precio

Not reported

Presentación

03/27/2026

Tipo

VENTA

Disbrow Joshua R.

Transacción: 03/26/2026

VENTA

Cambio

-89,501

Precio

Not reported

Presentación

03/27/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Cress Michael D	VENTA	-82,501	Not reported	03/26/2026	03/27/2026
Cress Michael D	VENTA	-12,499	Not reported	03/26/2026	03/27/2026
Disbrow Joshua R.	VENTA	-89,501	Not reported	03/26/2026	03/27/2026
Disbrow Joshua R.	VENTA	-12,499	Not reported	03/26/2026	03/27/2026
MICHAELS BARRY D	VENTA	-80,001	Not reported	03/26/2026	03/27/2026
MOORHEAD DANIEL J	VENTA	-2,314	$15.75	06/07/2021	06/08/2021
MOORHEAD DANIEL J	COMPRA	+5,000	Not reported	06/05/2021	06/08/2021

Sobre la compañía

Zynex, Inc.

Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

Fuente - Link

Competidores

ECOR EVAX GBIO HYPD JSPR MAIA MODD MURA MYO WGRX

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Kuehn Law Encourages Investors of Zynex, Inc. to Contact Law Firm

NEW YORK, July 21, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zynex, Inc. (NASDAQ: ZYXI) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Zynex misled investors about the Company's business, operations, and prospects, specifically failing to disclose: (1) that Zynex shipped products, including electrodes, in excess of need; (2) that, as a result of this practice, the Company inflated its revenue; (3) that the Company's practice of filing false claims drew scrutiny from insurers, including Tricare; (4) that, as a result, it was reasonably likely that Zynex would face adverse consequences, including removal from insurer networks and penalties from the federal government; and (5) that, as a result of the foregoing, positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

PRNewsWire

Kuehn Law Encourages Investors of Zynex, Inc. to Contact Law Firm

NEW YORK, July 13, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Zynex, Inc. (NASDAQ: ZYXI) breached their fiduciary duties to shareholders.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2025-11-17	-0.19	-0.41	-0.22
2025-07-31	-0.13	-0.32	-0.19
2025-04-28	-0.24	-0.33	-0.09
2025-03-11	0.09	-0.02	-0.11
2024-10-24	0.06	0.07	0.01
2024-07-25	0.08	0.04	-0.04
2024-02-29	0.17	0.04	-0.13
2023-10-26	0.09	0.1	0.01
2023-07-27	0.05	0.09	0.04
2023-04-27	0.01333	0.04	0.02667
2023-03-13	0.19	0.2	0.01
2022-10-27	0.12	0.13	0.01